Seminar Program Evonik Health Care

Sorry! This seminar has already taken place. Please see our event calendar for upcoming events.

Overview

Lipids are among the most clinically important excipients for drug delivery systems and are especially relevant for RNA-based therapies and mRNA vaccines. In this symposium, you will gain valuable insights into the use of lipids in drug delivery and the steps that lead to success. Our team will outline the role of our novel multivariate models to speed up timelines and increase successful scale up and transfer to the clinic. We will also highlight current advances in leveraging novel lipids, such as randomized PEGs (rPEGs), ionizable lipids in lipid nanoparticle (LNP)-based delivery systems and encapsulation technologies. As part of the symposium you will have the opportunity to network over lunch .

With decades of experience and expertise in every step of the manufacturing process, including route scouting, process development and optimization, purification, isolation, characterization, scale up and commercialization, Evonik is your partner to help your drug delivery project succeed.

Key learnings for participants
• Discover the essential capabilities required to support lipid development and manufacturing
• Learn about innovative techniques for liposome processing that can help you improve the efficiency and effectiveness of your drug delivery systems
• Explore the latest advancements in LNP formulation, including the use of randomized PEGs (rPEGs) and ionizable lipids, and how they can enhance the efficacy and safety of your drug delivery systems

Agenda

09:30 a.m.
Registration & welcome

10:00 a.m.
Welcome & introduction to Evonik Health Care
Dominic Walsh (Regional Business Manager UK)
Evonik Health Care

10:15 a.m.
Leading the way in Lipid production
Ulrich Klockner (Head of Process Development)
Evonik Health Care

11:00 a.m.
New families of ionizable lipids for effective delivery of RNA therapeutics
Dr. Diego De Miguel Samaniego (Formulation Manager)
CerTest Pharma

11:45 a.m.
Networking Lunch

1:00 p.m.
From PEG to rPEGs: A unique building block in next generation lipid nanoparticles
Dr. Sophie Hammer (Senior Manager Strategic & Technical Marketing)
Evonik Health Care

1:30 p.m.
3D printed microfluidic arrays for the development of liposomes
Prof. Dennis Dour (Professor in Pharmaceutical Technology and Process Engineering)
Greenwich University

2:00 p.m.
Overview of Evonik parenteral CDMO services
George Smith (Senior Business Manger Parenteral Services)
Evonik Health Care

2:15 p.m.
Wrap up and Goodbye

Experts

George Smith
Business Manager
Evonik Health Care

Dr. Ulrich Klöckner
Global Project Manager
Evonik Health Care
Vita

Dr. Ulrich Klöckner joined Evonik in 2017 and has held several R&D roles within the Evonik Health Care business. In his first positions as a laboratory head he was responsible for the process development and scale up of APIs and lipids. As a project manager in the CDMO business, he managed and led projects focusing on APIs and lipids manufacturing under cGMP.

Since 2022, as a global project manager, Ulrich is responsible for the project management and serves as the technical contact of Evonik Health Care’s lipid business. Ulrich is an organic chemist by education and obtained his PhD from the University of Tuebingen in Germany. As a postdoctoral fellow, holding a DFG scholarship, he went to the University of Urbana Champaign in Illinois, USA. Ulrich is author of numerous research papers and patent applications.

Dominic Walsh
Business Manager
Evonik Health Care

Dr. Sophie Hammer
Senior Manager Strategic & Technical Marketing
Evonik Health Care

Prof. Dr. Dennis Douroumis
Professor in Pharmaceutical Technology and Process Engineering
Greenwich University
Vita

Dr. Dennis Douroumis is a professor in Pharmaceutical Technology and Process Engineering at the University of Greenwich, UK

His research activities focus on emerging technologies including:
(a) Continuous manufacturing processes for the development of medicinal products,
(b) 3D printing technologies for novel medical devices (microneedles, bioresorbable scaffolds), and
(c) Nanomaterial synthesis and surface modification for cancer treatment.

Dennis has established several national and international collaborations with world-class colleagues/researchers including funded projects by pharmaceutical companies and several EU/UK grants. He received the prestigious award of Eminent Fellowship of the Academy of Pharmaceutical Sciences for the excellence in the pharmaceutical sciences over a prolonged period with an emphasis on advocacy and leadership. He has also received several awards from the American Association of Pharmaceutical Sciences (AAPS) and the American Chemical Society (ACS).

Dr. Diego de Miguel Samaniego
Formulation Manager
CerTest Pharma
Vita

Dr. Diego de Miguel is an expert in lipid nanoparticles and cellular biology, with a strong background in immunology, cell death and inflammatory pathways. At Certest Pharma, he leads the discovery of next generation LNP formulations to enable novel targeted therapeutic applications.
Diego de Miguel obtained his Bachelor’s degree in Biochemistry at the University of Zaragoza in 2009, followed by a MsC in Cellular Biology in 2010. During his PhD, Dr. de Miguel mainly focused on the use of lipid nanoparticles as platform for delivering death ligands and chemotherapeutic drugs to cancer and immune cells. During this period, he engineered lipid nanoparticles by functionalizing them with targeting motifs and optimized their lipid composition to enhance their efficacy.
After his PhD, Dr. de Miguel joined Prof. Henning Walczak’s laboratory at the UCL Cancer Institute, where he focused on the molecular study of different pro-inflammatory signalling pathways, especially Apo2L/TRAIL, TNF and TLR3. After 4 years of post-doctoral experience abroad, Dr. de Miguel returned to Spain, seeking to apply his expertise in cell death and inflammation to more translational models of immunity, deepening the understanding of the inflammatory and cytotoxic mechanisms of NK cells and T cells.
In 2021, Dr. de Miguel joined Certest as Manager of the LNP Formulation Department to embark upon the development of mRNA vaccines using lipid nanoparticles (LNP). In this role, he oversees exploring new LNP formulations incorporating Certest lipids, aiming at optimizing their efficiency. Moreover, Dr. de Miguel is in charge of designing new formulations with targeting capabilities towards specific tissues or cell types to enable a more precise delivery of the LNPs. Finally, his department has also developed a successful lyophilization process for lipid nanoparticles which remove the need for freezing temperatures for the storage and shipping of LNP-based therapeutics.

Details

Participation fee:: Free of charge
City/State:: Cambridge
Country:: United Kingdom
Seminar language:: English

Venue

The workshop will take place at:

Babraham Research Campus
Babraham Hall, Babraham, Cambridge CB22 3AT, United Kingdom

Questions?

George Smith
Business Manager
Evonik Health Care

+44 7496 25 7839 E-Mail